Abstract
In Parkinson disease (PD), affected midbrain dopamine (DA) neurons lose specific dopaminergic properties before the neurons die. How the phenotype of DA neurons is normally established and the ways in which pathology affects the maintenance of cell identity are, therefore, important considerations. Orphan nuclear receptor NURR1 (NURR1, also known as NR4A2) is involved in the differentiation of midbrain DA neurons, but also has an important role in the adult brain. Emerging evidence indicates that impaired NURR1 function might contribute to the pathogenesis of PD: NURR1 and its transcriptional targets are downregulated in midbrain DA neurons that express high levels of the disease-causing protein α-synuclein. Clinical and experimental data indicate that disrupted NURR1 function contributes to induction of DA neuron dysfunction, which is seen in early stages of PD. The likely involvement of NURR1 in the development and progression of PD makes this protein a potentially interesting target for therapeutic intervention.
Key Points
-
NURR1 and other transcription factors that are essential for the development and specification of midbrain dopamine neurons during development continue to have an important role in the adult brain
-
Deletion of NURR1 in mature dopamine neurons results in progressive pathology, reduction in dopamine neuron markers and motor impairments—recapitulating early features of Parkinson disease
-
Ablation of Nurr1 in adult rodents results in reduced expression of genes associated with mitochondrial function and oxidative phosphorylation, suggesting a role for Nurr1 in the maintenance of midbrain dopamine neurons
-
NURR1 and its transcriptional targets are downregulated in midbrain dopamine neurons that express high levels of the disease-causing protein α-synuclein, as observed in rodent models and patients with Parkinson disease
-
α-Synuclein overexpression results in an almost complete blockade of GDNF trophic signalling and failure of GDNF to protect against α-synuclein-induced toxicity in affected neurons
-
Reduced NURR1 expression might result in induction of dopamine neuron dysfunction as well progression of degenerative changes, which could make this protein a promising therapeutic target
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055–2066 (2009).
Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725 (2010).
Wang, Z. et al. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423, 555–560 (2003).
Baker, K. D. et al. The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell 113, 731–742 (2003).
Perlmann, T. & Jansson, L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev. 9, 769–782 (1995).
Smidt, M. P. & Burbach, J. P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 8, 21–32 (2007).
Zetterstrom, R. H. et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248–250 (1997).
Le, W., Conneely, O. M., He, Y., Jankovic, J. & Appel, S. H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73, 2218–2221 (1999).
Pan, T. et al. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 1222, 222–229 (2008).
Luo, Y., Wang, Y., Kuang, S. Y., Chiang, Y. H. & Hoffer, B. Decreased level of Nurr1 in heterozygous young adult mice leads to exacerbated acute and long-term toxicity after repeated methamphetamine exposure. PLoS ONE 5, e15193 (2010).
Jiang, C. et al. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191, 154–162 (2005).
Kadkhodaei, B. et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29, 15923–15932 (2009).
Kadkhodaei, B. et al. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc. Natl Acad. Sci. USA 110, 2360–2365 (2013).
Zheng, K., Heydari, B. & Simon, D. K. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 60, 722–725 (2003).
Chen, C. M. et al. Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 458–462 (2007).
Liu, H. et al. Genetic analysis of NR4A2 gene in a large population of Han Chinese patients with Parkinson's disease. Eur. J. Neurol. 20, 584–587 (2013).
Wu, Y. et al. Association of the polymorphisms in NURR1 gene with Parkinson's disease [Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25, 693–696 (2008).
Tan, E. K. et al. Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neurosci. Lett. 347, 139–142 (2003).
Le, W. D. et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33, 85–89 (2003).
Sleiman, P. M. et al. Characterisation of a novel NR4A2 mutation in Parkinson's disease brain. Neurosci. Lett. 457, 75–79 (2009).
Hering, R. et al. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 62, 1231–1232 (2004).
Jacobsen, K. X. et al. A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol. Dis. 29, 117–122 (2008).
Grimes, D. A. et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov. Disord. 21, 906–909 (2006).
Moran, L. B. et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol. 113, 253–263 (2007).
Chu, Y. et al. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 494, 495–514 (2006).
Chu, Y., Kompoliti, K., Cochran, E. J., Mufson, E. J. & Kordower, J. H. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J. Comp. Neurol. 450, 203–214 (2002).
Chu, Y. P. & Kordower, J. H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134–149 (2007).
Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283–2301 (1991).
Le, W. et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J. Neurol. Sci. 273, 29–33 (2008).
Liu, H. et al. Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson's disease. Eur. J. Neurol. 19, 870–875 (2012).
Pan, T. H., Xie, W. J., Jankovic, J. & Le, W. D. Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease. Neurology 62, A108–A108 (2004).
Saucedo-Cardenas, O. et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl Acad. Sci. USA 95, 4013–4018 (1998).
Eells, J. B., Misler, J. A. & Nikodem, V. M. Reduced tyrosine hydroxylase and GTP cyclohydrolase mRNA expression, tyrosine hydroxylase activity, and associated neurochemical alterations in Nurr1-null heterozygous mice. Brain Res. Bull. 70, 186–195 (2006).
Jacobs, F. M. et al. Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons. Development 136, 2363–2373 (2009).
Hermanson, E. et al. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp. Cell Res. 288, 324–334 (2003).
Smits, S. M., Ponnio, T., Conneely, O. M., Burbach, J. P. & Smidt, M. P. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur. J. Neurosci. 18, 1731–1738 (2003).
Gil, M. et al. Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo. J. Neurochem. 101, 142–150 (2007).
Luo, Y. et al. VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp. Neurol. 203, 221–232 (2007).
Heng, X. et al. Nurr1 regulates Top IIβ and functions in axon genesis of mesencephalic dopaminergic neurons. Mol. Neurodegener. 7, 4 (2012).
Joseph, B. et al. p57Kip2 cooperates with Nurr1 in developing dopamine cells. Proc. Natl Acad. Sci. USA 100, 15619–15624 (2003).
Galleguillos, D. et al. Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain. J. Neurochem. 114, 1158–1167 (2010).
Wallen, A. A. et al. Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol. Cell. Neurosci. 18, 649–663 (2001).
Exner, N., Lutz, A. K., Haass, C. & Winklhofer, K. F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038–3062 (2012).
Zheng, B. et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73 (2010).
Puigserver, P. & Spiegelman, B. M. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24, 78–90 (2003).
Doble, A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163–221 (1999).
Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634–1658 (2006).
Volakakis, N. et al. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc. Natl Acad. Sci. USA 107, 12317–12322 (2010).
Zhang, S. J. et al. Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal survival and death. Neuron 53, 549–562 (2007).
Zhang, S. J. et al. Nuclear calcium signaling controls expression of a large gene pool: identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet. 5, e1000604 (2009).
Xiang, G. et al. Identification of activity-dependent gene expression profiles reveals specific subsets of genes induced by different routes of Ca2+ entry in cultured rat cortical neurons. J. Cell. Physiol. 212, 126–136 (2007).
Pegoraro, S. et al. Sequential steps underlying neuronal plasticity induced by a transient exposure to gabazine. J. Cell. Physiol. 222, 713–728 (2010).
Barneda-Zahonero, B. et al. Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival. J. Biol. Chem. 287, 11351–11362 (2012).
Lee, M. A. et al. Overexpression of midbrain-specific transcription factor Nurr1 modifies susceptibility of mouse neural stem cells to neurotoxins. Neurosci. Lett. 333, 74–78 (2002).
Sousa, K. M. et al. Microarray analyses support a role for Nurr1 in resistance to oxidative stress and neuronal differentiation in neural stem cells. Stem Cells 25, 511–519 (2007).
Jo, A. Y. et al. Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant. Stem Cells 27, 2238–2246 (2009).
Shin, J. H. et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689–702 (2011).
Pacelli, C. et al. Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease. Biochim. Biophys. Acta 1812, 1041–1053 (2011).
Deleidi, M. & Gasser, T. The role of inflammation in sporadic and familial Parkinson's disease. Cell. Mol. Life Sci. http://dx.doi.org/10.1007/s00018-013-1352-y.
Saijo, K. et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137, 47–59 (2009).
Kramer, E. R. et al. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 5, e39 (2007).
Pascual, A. et al. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11, 755–761 (2008).
Eggert, K. et al. Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci. Lett. 269, 178–182 (1999).
Hou, J. G., Lin, L. F. & Mytilineou, C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66, 74–82 (1996).
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S. & Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130–1132 (1993).
Choi-Lundberg, D. L. et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838–841 (1997).
Gash, D. M. et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252–255 (1996).
Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191–2201 (2002).
Kirik, D., Rosenblad, C., Bjorklund, A. & Mandel, R. J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20, 4686–4700 (2000).
Sauer, H., Rosenblad, C. & Bjorklund, A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl Acad. Sci. USA 92, 8935–8939 (1995).
Tomac, A. et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335–339 (1995).
Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459–466 (2006).
Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589–595 (2003).
Nutt, J. G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69–73 (2003).
Bartus, R. T. et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26, 27–36 (2011).
Marks, W. J. Jr et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164–1172 (2010).
Decressac, M. et al. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain 134, 2302–2311 (2011).
Lo Bianco, C., Deglon, N., Pralong, W. & Aebischer, P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 17, 283–289 (2004).
Decressac, M. et al. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 163, 163ra156 (2012).
Lin, X. et al. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 32, 9248–9264 (2012).
Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W. & Kordower, J. H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398 (2009).
Crews, L. et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of α-synucleinopathy. PLoS ONE 5, e9313 (2010).
Dehay, B. et al. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535–12544 (2010).
Chu, Y., Mickiewicz, A. L. & Kordower, J. H. α-Synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol. Dis. 41, 71–82 (2011).
Decressac, M. et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl Acad. Sci. USA 110, E1817–E1826 (2013).
Desplats, P. et al. α-Synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J. Biol. Chem. 286, 9031–9037 (2011).
Azeredo da Silveira, S. et al. Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 18, 872–887 (2009).
Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 (2000).
McLean, P. J., Ribich, S. & Hyman, B. T. Subcellular localization of α-synuclein in primary neuronal cultures: effect of missense mutations. J. Neural Transm. Suppl. 2000, 53–63 (2000).
Specht, C. G. et al. Subcellular localisation of recombinant α- and γ-synuclein. Mol. Cell. Neurosci. 28, 326–334 (2005).
Takahashi, M. et al. Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155–158 (2003).
Cooper-Knock, J. et al. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8, 518–530 (2012).
Kontopoulos, E., Parvin, J. D. & Feany, M. B. α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012–3023 (2006).
Jin, H. et al. α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J. Neurosci. 31, 2035–2051 (2011).
Siddiqui, A. et al. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 53, 993–1003 (2012).
Outeiro, T. F. et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516–519 (2007).
Chintharlapalli, S. et al. Activation of Nur77 by selected 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J. Biol. Chem. 280, 24903–24914 (2005).
Dubois, C., Hengerer, B. & Mattes, H. Identification of a potent agonist of the orphan nuclear receptor Nurr1. ChemMedChem 1, 955–958 (2006).
Hintermann, S. et al. Identification of a series of highly potent activators of the Nurr1 signaling pathway. Bioorg. Med. Chem. Lett. 17, 193–196 (2007).
Inamoto, T. et al. 1,1-Bis(3′-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol. Cancer Ther. 7, 3825–3833 (2008).
Li, X., Lee, S. O. & Safe, S. Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3′-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells. Biochem. Pharmacol. 83, 1445–1455 (2012).
Ordentlich, P., Yan, Y., Zhou, S. & Heyman, R. A. Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J. Biol. Chem. 278, 24791–24799 (2003).
Poppe, L. et al. Discovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies. J. Biomol. Screen 12, 301–311 (2007).
Wansa, K. D., Harris, J. M., Yan, G., Ordentlich, P. & Muscat, G. E. The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J. Biol. Chem. 278, 24776–24790 (2003).
Zhang, Z. et al. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol. Disord. Drug Targets 11, 768–773 (2012).
Wallen-Mackenzie, A. et al. Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev. 17, 3036–3047 (2003).
Morita, K. et al. Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1. Biochem. Pharmacol. 71, 98–107 (2005).
Bartus, R. T. et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698–1701 (2013).
Acknowledgements
We thank members in our laboratories for valuable discussions. This work was supported by grants from the Swedish Research Council via a Linnaeus grant (A. Björklund & T. Perlmann), the Swedish Strategic Research Foundation (A. Björklund & T. Perlmann) and the Michael J. Fox Foundation (A. Björklund & T. Perlmann). We apologize to the authors of the many interesting studies that could not be included in this Review owing to space constraints.
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, provided substantial discussion of content, contributed to writing the article, and review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Decressac, M., Volakakis, N., Björklund, A. et al. NURR1 in Parkinson disease—from pathogenesis to therapeutic potential. Nat Rev Neurol 9, 629–636 (2013). https://doi.org/10.1038/nrneurol.2013.209
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.209
This article is cited by
-
Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway
Cell Death & Disease (2024)
-
Aberrant somatic calcium channel function in cNurr1 and LRRK2-G2019S mice
npj Parkinson's Disease (2023)
-
An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models
Nature Communications (2023)
-
The role of NURR1 in metabolic abnormalities of Parkinson’s disease
Molecular Neurodegeneration (2022)
-
Transcriptomic analysis in the striatum reveals the involvement of Nurr1 in the social behavior of prenatally valproic acid-exposed male mice
Translational Psychiatry (2022)